Trial Profile

Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent N-803 in Adults With COVID-19

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nogapendekin alfa inbakicept (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors ImmunityBio

Most Recent Events

05 Sep 2024 The protocol has been amended to change in study primary endpoint now the AEs will be assessed.
05 Sep 2024 Status changed from active, no longer recruiting to discontinued.
26 May 2021 Planned End Date changed from 11 Jul 2020 to 11 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com